Lower chemotherapy dose after half-matched stem cell transplant for blood cancer
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a lower dose of the drug cyclophosphamide after a stem cell transplant from a half-matched donor. It aims to see if the lower dose works just as well to prevent graft-versus-host disease, with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a blood cancer that needs a stem cell transplant
- You have a half-matched (haploidentical) donor willing to donate stem cells
- Your planned transplant uses a chemotherapy called thiotepa
- You agree to use effective birth control during the study and for 6 months after the last dose (if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a lower dose of the chemotherapy drug cyclophosphamide given after a stem cell transplant is safe and effective for people with blood cancers. The goal is to reduce side effects while still helping prevent the cancer from coming back.
This trial tests whether a lower dose of a common drug (cyclophosphamide) after transplant can prevent graft-versus-host disease (a complication where donor cells attack your body) just as well as the standard dose. It also uses another medicine (anti-thymocyte globulin) after the transplant to help protect you.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
This trial tests a stem cell transplant using a reduced-intensity chemotherapy regimen and a low dose of a drug called cyclophosphamide after the transplant to help prevent graft-versus-host disease (GVHD), a common complication where donor cells attack the recipient's body. It is for people with certain blood cancers or bone marrow disorders who have a suitable donor.
This trial tests whether giving a lower dose of cyclophosphamide after a bone marrow transplant can be safer for older or medically “unfit” patients, while still helping control blood cancers. It is designed for people who can’t tolerate the usual strongest transplant preparation.
Hear when a new GVHD - Graft-Versus-Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.